Cargando…

Differences in the serum metabolome and lipidome identify potential biomarkers for seronegative rheumatoid arthritis versus psoriatic arthritis

OBJECTIVES: The differential diagnosis of seronegative rheumatoid arthritis (negRA) and psoriasis arthritis (PsA) is often difficult due to the similarity of symptoms and the unavailability of reliable clinical markers. Since chronic inflammation induces major changes in the serum metabolome and lip...

Descripción completa

Detalles Bibliográficos
Autores principales: Souto-Carneiro, Margarida, Tóth, Lilla, Behnisch, Rouven, Urbach, Konstantin, Klika, Karel D, Carvalho, Rui A, Lorenz, Hanns-Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7147174/
https://www.ncbi.nlm.nih.gov/pubmed/32079570
http://dx.doi.org/10.1136/annrheumdis-2019-216374
_version_ 1783520367704276992
author Souto-Carneiro, Margarida
Tóth, Lilla
Behnisch, Rouven
Urbach, Konstantin
Klika, Karel D
Carvalho, Rui A
Lorenz, Hanns-Martin
author_facet Souto-Carneiro, Margarida
Tóth, Lilla
Behnisch, Rouven
Urbach, Konstantin
Klika, Karel D
Carvalho, Rui A
Lorenz, Hanns-Martin
author_sort Souto-Carneiro, Margarida
collection PubMed
description OBJECTIVES: The differential diagnosis of seronegative rheumatoid arthritis (negRA) and psoriasis arthritis (PsA) is often difficult due to the similarity of symptoms and the unavailability of reliable clinical markers. Since chronic inflammation induces major changes in the serum metabolome and lipidome, we tested whether differences in serum metabolites and lipids could aid in improving the differential diagnosis of these diseases. METHODS: Sera from negRA and PsA patients with established diagnosis were collected to build a biomarker-discovery cohort and a blinded validation cohort. Samples were analysed by proton nuclear magnetic resonance. Metabolite concentrations were calculated from the spectra and used to select the variables to build a multivariate diagnostic model. RESULTS: Univariate analysis demonstrated differences in serological concentrations of amino acids: alanine, threonine, leucine, phenylalanine and valine; organic compounds: acetate, creatine, lactate and choline; and lipid ratios L3/L1, L5/L1 and L6/L1, but yielded area under the curve (AUC) values lower than 70%, indicating poor specificity and sensitivity. A multivariate diagnostic model that included age, gender, the concentrations of alanine, succinate and creatine phosphate and the lipid ratios L2/L1, L5/L1 and L6/L1 improved the sensitivity and specificity of the diagnosis with an AUC of 84.5%. Using this biomarker model, 71% of patients from a blinded validation cohort were correctly classified. CONCLUSIONS: PsA and negRA have distinct serum metabolomic and lipidomic signatures that can be used as biomarkers to discriminate between them. After validation in larger multiethnic cohorts this diagnostic model may become a valuable tool for a definite diagnosis of negRA or PsA patients.
format Online
Article
Text
id pubmed-7147174
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-71471742020-04-15 Differences in the serum metabolome and lipidome identify potential biomarkers for seronegative rheumatoid arthritis versus psoriatic arthritis Souto-Carneiro, Margarida Tóth, Lilla Behnisch, Rouven Urbach, Konstantin Klika, Karel D Carvalho, Rui A Lorenz, Hanns-Martin Ann Rheum Dis Psoriatic Arthritis OBJECTIVES: The differential diagnosis of seronegative rheumatoid arthritis (negRA) and psoriasis arthritis (PsA) is often difficult due to the similarity of symptoms and the unavailability of reliable clinical markers. Since chronic inflammation induces major changes in the serum metabolome and lipidome, we tested whether differences in serum metabolites and lipids could aid in improving the differential diagnosis of these diseases. METHODS: Sera from negRA and PsA patients with established diagnosis were collected to build a biomarker-discovery cohort and a blinded validation cohort. Samples were analysed by proton nuclear magnetic resonance. Metabolite concentrations were calculated from the spectra and used to select the variables to build a multivariate diagnostic model. RESULTS: Univariate analysis demonstrated differences in serological concentrations of amino acids: alanine, threonine, leucine, phenylalanine and valine; organic compounds: acetate, creatine, lactate and choline; and lipid ratios L3/L1, L5/L1 and L6/L1, but yielded area under the curve (AUC) values lower than 70%, indicating poor specificity and sensitivity. A multivariate diagnostic model that included age, gender, the concentrations of alanine, succinate and creatine phosphate and the lipid ratios L2/L1, L5/L1 and L6/L1 improved the sensitivity and specificity of the diagnosis with an AUC of 84.5%. Using this biomarker model, 71% of patients from a blinded validation cohort were correctly classified. CONCLUSIONS: PsA and negRA have distinct serum metabolomic and lipidomic signatures that can be used as biomarkers to discriminate between them. After validation in larger multiethnic cohorts this diagnostic model may become a valuable tool for a definite diagnosis of negRA or PsA patients. BMJ Publishing Group 2020-04 2020-02-20 /pmc/articles/PMC7147174/ /pubmed/32079570 http://dx.doi.org/10.1136/annrheumdis-2019-216374 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Psoriatic Arthritis
Souto-Carneiro, Margarida
Tóth, Lilla
Behnisch, Rouven
Urbach, Konstantin
Klika, Karel D
Carvalho, Rui A
Lorenz, Hanns-Martin
Differences in the serum metabolome and lipidome identify potential biomarkers for seronegative rheumatoid arthritis versus psoriatic arthritis
title Differences in the serum metabolome and lipidome identify potential biomarkers for seronegative rheumatoid arthritis versus psoriatic arthritis
title_full Differences in the serum metabolome and lipidome identify potential biomarkers for seronegative rheumatoid arthritis versus psoriatic arthritis
title_fullStr Differences in the serum metabolome and lipidome identify potential biomarkers for seronegative rheumatoid arthritis versus psoriatic arthritis
title_full_unstemmed Differences in the serum metabolome and lipidome identify potential biomarkers for seronegative rheumatoid arthritis versus psoriatic arthritis
title_short Differences in the serum metabolome and lipidome identify potential biomarkers for seronegative rheumatoid arthritis versus psoriatic arthritis
title_sort differences in the serum metabolome and lipidome identify potential biomarkers for seronegative rheumatoid arthritis versus psoriatic arthritis
topic Psoriatic Arthritis
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7147174/
https://www.ncbi.nlm.nih.gov/pubmed/32079570
http://dx.doi.org/10.1136/annrheumdis-2019-216374
work_keys_str_mv AT soutocarneiromargarida differencesintheserummetabolomeandlipidomeidentifypotentialbiomarkersforseronegativerheumatoidarthritisversuspsoriaticarthritis
AT tothlilla differencesintheserummetabolomeandlipidomeidentifypotentialbiomarkersforseronegativerheumatoidarthritisversuspsoriaticarthritis
AT behnischrouven differencesintheserummetabolomeandlipidomeidentifypotentialbiomarkersforseronegativerheumatoidarthritisversuspsoriaticarthritis
AT urbachkonstantin differencesintheserummetabolomeandlipidomeidentifypotentialbiomarkersforseronegativerheumatoidarthritisversuspsoriaticarthritis
AT klikakareld differencesintheserummetabolomeandlipidomeidentifypotentialbiomarkersforseronegativerheumatoidarthritisversuspsoriaticarthritis
AT carvalhoruia differencesintheserummetabolomeandlipidomeidentifypotentialbiomarkersforseronegativerheumatoidarthritisversuspsoriaticarthritis
AT lorenzhannsmartin differencesintheserummetabolomeandlipidomeidentifypotentialbiomarkersforseronegativerheumatoidarthritisversuspsoriaticarthritis